Canada markets close in 2 hours 38 minutes

Gritstone bio, Inc. (GRTS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.0150-0.1250 (-5.84%)
As of 01:22PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close2.1400
Open2.1000
Bid2.0200 x 1100
Ask2.0300 x 2200
Day's Range2.0100 - 2.1000
52 Week Range2.0000 - 14.4200
Volume434,448
Avg. Volume1,316,325
Market Cap146.718M
Beta (5Y Monthly)0.37
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Gritstone to Participate in H.C. Wainwright Global Investment Conference

    EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer of Gritstone, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference, which is being held virtually and in-person from May 23-26, 2022. The fireside chat will be available on-demand begi

  • GlobeNewswire

    CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update

    -- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines against viruses expected over the next 18 months -- -- Recent presentations reinforce expertise in vaccine design and delivery and potential of Gritstone’s platform technologies in oncology and infectious diseases -- -- Cash, cash equivalents, marketable securities and restricted cash of $186.8 millio

  • GlobeNewswire

    Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update

    -- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines against viruses expected over the next 18 months -- -- Recent presentations reinforce expertise in vaccine design and delivery and potential of Gritstone’s platform technologies in oncology and infectious diseases -- -- Cash, cash equivalents, marketable securities and restricted cash of $186.8 millio